Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-12-08

Clinical Trial Update: HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB) [Phase 2]

View source ↗

Summary

A Phase 2 trial of HepTcell immunotherapy in patients with inactive chronic hepatitis B was terminated, and results were posted on December 8, 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • HepTcell Immunotherapy

Snippet

Sponsor: Altimmune, Inc. | Conditions: Hepatitis B, Chronic | Phase 2 | Status: TERMINATED | Results posted: 2025-12-08